The treatment, also known as abemaciclib, is approved to treat certain forms of breast cancer but not prevent cancer from recurring, and analysts estimate the data could add billions to its sales. About 30% of patients with a common subtype of early breast cancer that the drug targets are at a high-risk of their cancer returning, despite progress in the treatment. “Assuming 40%-50% penetration into this high risk population translates to an about $2 billion incremental market opportunity,” J.P. Morgan analyst Chris Schott said in a note to clients.
from Yahoo Finance https://ift.tt/37yB1fC
Leave a Reply